ADCT Fundamental Analysis - ADC THERAPEUTICS SA

Fundamental Rating

Overall ADCT gets a fundamental rating of 2 out of 10. We evaluated ADCT against 530 industry peers in the Biotechnology industry. ADCT may be in some trouble as it scores bad on both profitability and health. ADCT is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ADCT has reported negative net income.

ADCT had a negative operating cash flow in the past year.

In the past 5 years ADCT always reported negative net income.

ADCT had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

With a Return On Assets value of -57.61%, ADCT perfoms like the industry average, outperforming 43.40% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-57.61%
ROE	N/A
ROIC	N/A

ROA(3y)-48.71%

ROA(5y)-46.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ADCT's Gross Margin of 92.73% is amongst the best of the industry. ADCT outperforms 93.40% of its industry peers.

In the last couple of years the Gross Margin of ADCT has declined.

The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	92.73%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.51%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ADCT has been increased compared to 1 year ago.

Compared to 5 years ago, ADCT has more shares outstanding

Compared to 1 year ago, ADCT has a worse debt to assets ratio.

2.2 Solvency

ADCT has an Altman-Z score of -7.56. This is a bad value and indicates that ADCT is not financially healthy and even has some risk of bankruptcy.

With a Altman-Z score value of -7.56, ADCT is not doing good in the industry: 68.11% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-7.56

ROIC/WACCN/A

WACC4.53%

2.3 Liquidity

ADCT has a Current Ratio of 4.63. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.

ADCT has a Current ratio (4.63) which is in line with its industry peers.

ADCT has a Quick Ratio of 4.34. This indicates that ADCT is financially healthy and has no problem in meeting its short term obligations.

ADCT has a Quick ratio (4.34) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.63
Quick Ratio	4.34

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 44.35% over the past year.

Looking at the last year, ADCT shows a very negative growth in Revenue. The Revenue has decreased by -39.09% in the last year.

ADCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.48% yearly.

EPS 1Y (TTM)44.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%28.57%

Revenue 1Y (TTM)-39.09%

Revenue growth 3Y27.85%

Revenue growth 5Y98.48%

Sales Q2Q%-11.03%

3.2 Future

The Earnings Per Share is expected to grow by 15.39% on average over the next years. This is quite good.

The Revenue is expected to grow by 33.94% on average over the next years. This is a very strong growth

EPS Next Y12.63%

EPS Next 2Y14.62%

EPS Next 3Y15.39%

EPS Next 5YN/A

Revenue Next Year5.27%

Revenue Next 2Y4.57%

Revenue Next 3Y26.8%

Revenue Next 5Y33.94%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ADCT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ADCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ADCT's earnings are expected to grow with 15.39% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y14.62%

EPS Next 3Y15.39%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ADCT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADC THERAPEUTICS SA

NYSE:ADCT (12/23/2025, 5:44:00 PM)

After market: 3.56 +0.06 (+1.71%)

3.5

-0.2 (-5.41%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-10 2025-11-10/bmo

Earnings (Next)03-25 2026-03-25/amc

Inst Owners53.82%

Inst Owner Change-0.59%

Ins Owners5.27%

Ins Owner Change-1.45%

Market Cap433.58M

Revenue(TTM)75.21M

Net Income(TTM)-166.94M

Analysts86.67

Price Target8.16 (133.14%)

Short Float %6%

Short Ratio4.79

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)20.04%

Min EPS beat(2)18.68%

Max EPS beat(2)21.4%

EPS beat(4)4

Avg EPS beat(4)20.88%

Min EPS beat(4)12.49%

Max EPS beat(4)30.94%

EPS beat(8)6

Avg EPS beat(8)-0.22%

EPS beat(12)7

Avg EPS beat(12)-2.22%

EPS beat(16)10

Avg EPS beat(16)1.26%

Revenue beat(2)1

Avg Revenue beat(2)-1.14%

Min Revenue beat(2)-5.69%

Max Revenue beat(2)3.41%

Revenue beat(4)2

Avg Revenue beat(4)3.11%

Min Revenue beat(4)-12.78%

Max Revenue beat(4)27.51%

Revenue beat(8)3

Avg Revenue beat(8)0.81%

Revenue beat(12)4

Avg Revenue beat(12)-4.76%

Revenue beat(16)7

Avg Revenue beat(16)2.72%

PT rev (1m)0%

PT rev (3m)-3.03%

EPS NQ rev (1m)5.94%

EPS NQ rev (3m)12.12%

EPS NY rev (1m)7.32%

EPS NY rev (3m)6.28%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0.37%

Revenue NY rev (1m)-1.27%

Revenue NY rev (3m)-2.42%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.77
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-1.33

EYN/A

EPS(NY)-1.13

Fwd EYN/A

FCF(TTM)-1.07

FCFYN/A

OCF(TTM)-1.06

OCFYN/A

SpS0.61

BVpS-1.92

TBVpS-1.92

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-57.61%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	92.73%
FCFM	N/A

ROA(3y)-48.71%

ROA(5y)-46.26%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.51%

GM growth 5YN/A

F-Score2

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	-79.73%
Cap/Sales	0.47%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4.63
Quick Ratio	4.34
Altman-Z	-7.56

F-Score2

WACC4.53%

ROIC/WACCN/A

Cap/Depr(3y)144.88%

Cap/Depr(5y)161.59%

Cap/Sales(3y)2.31%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)44.35%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%28.57%

EPS Next Y12.63%

EPS Next 2Y14.62%

EPS Next 3Y15.39%

EPS Next 5YN/A

Revenue 1Y (TTM)-39.09%

Revenue growth 3Y27.85%

Revenue growth 5Y98.48%

Sales Q2Q%-11.03%

Revenue Next Year5.27%

Revenue Next 2Y4.57%

Revenue Next 3Y26.8%

Revenue Next 5Y33.94%

EBIT growth 1Y53.62%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-21.15%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y6.01%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y4.21%

OCF growth 3YN/A

OCF growth 5YN/A

ADC THERAPEUTICS SA / ADCT FAQ

Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?

ChartMill assigns a fundamental rating of 2 / 10 to ADCT.

What is the valuation status for ADCT stock?

ChartMill assigns a valuation rating of 0 / 10 to ADC THERAPEUTICS SA (ADCT). This can be considered as Overvalued.

Can you provide the profitability details for ADC THERAPEUTICS SA?

ADC THERAPEUTICS SA (ADCT) has a profitability rating of 1 / 10.

What is the financial health of ADC THERAPEUTICS SA (ADCT) stock?

The financial health rating of ADC THERAPEUTICS SA (ADCT) is 2 / 10.

ADC THERAPEUTICS SA (ADCT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

ADC THERAPEUTICS SA / ADCT FAQ

Can you provide the ChartMill fundamental rating for ADC THERAPEUTICS SA?

What is the valuation status for ADCT stock?

Can you provide the profitability details for ADC THERAPEUTICS SA?

What is the financial health of ADC THERAPEUTICS SA (ADCT) stock?